

pure[®]
biologics



SEP 2020

Disclaimer

By reading this Presentation ('Presentation') you agree to the following restrictions:

The information contained herein has been prepared by Pure Biologics S.A. ('Company', 'Issuer') solely for information purposes for investors. This Presentation is of a corporate character and does not constitute an offer, and does not form a part of an offer and should not be treated as the solicitation of an offer to purchase, sale or subscribe any securities or as an encouragement to such an offer, neither as marketing material in accordance with the above. The Issuer does not bear any responsibility for consequences of any decisions or actions taken on the basis of this Presentation. The responsibility for consequences of such actions and decisions rests solely on the user of this Presentation. Investing in Issuer's securities involves risk specific to capital market instruments as well as risk related to Issuer's business activity and the environment in which Issuer's activity takes place.

Presentation contains forward-looking statements that reflect current assessment by the Company or, depending on the context, its Management Board, regarding external factors, business strategy, plans and objectives of the Issuer regarding its future operations. Forward-looking statements relate to the Issuer as well as economic sectors and industries in which the Issuer operates. Such forward-looking statements can be identified by the use of terminology referring to the future, such as e.g. "may", "will be", "anticipates", "is expected", "should", "estimates", "believes", "think", "assume", or, in each case, their negatives or other variations or comparable terms. Forward-looking statements involve known and unknown risk and uncertainty, and other factors that may affect Company's actual results, performances and achievements and cause that actual results, performances and achievements will differ materially from any of the expected future results. Subject to the binding provisions of law, the Company disclaims any obligation to release publicly any updates or revisions to any forward-looking statements contained herein upon the occurrence of any future events, becoming aware of any new information or the occurrence of any other circumstances. Any future forward-looking statements, both written and oral, related to the Issuer or persons acting on behalf of the Issuer are expressly and entirely subject to the provisions of this paragraph. Neither Issuer nor any of its associated entities, advisers or representatives intend to prepare or disseminate any annexes, changes, updates or re-reviews of any information, opinion or forward-looking statement contained in the Presentation to reflect changes in events, conditions or circumstances and declares that it is under no obligation to take such actions. No statement, assurance or obligation, express or implied, regarding the accuracy, completeness and correctness of the information or opinion contained in this Presentation is made. Neither the Issuer nor any of its associated entities, advisers or representatives will bear responsibility or liability resulting from any damages arising in connection with the use of Presentation, its content or on any account whatsoever connected with Presentation. The Presentation is of solely informative character and does not constitute Prospectus as defined by EU Regulation 2017/1129 (as amended) (such Regulation, together with any applicable implementing measures in the relevant home Member State under such Regulation and other applicable regulations, the "Prospectus Regulation") or any securities note or encouragement regarding securities trading, in particular does not constitute an offer of sale or any solicitation of an offer to acquire or subscribe any securities. Providing access to Presentation does not constitute advertisement as defined by Prospectus Regulation or Public Offer of Financial Instruments Act.

THE INFORMATION CONTAINED HEREIN IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA OR TO U.S. PERSONS (ACCORDING TO THE DEFINITION OF THE TERM CONTAINED IN REGULATION S ISSUED ON THE BASIS OF THE US SECURITIES ACT OF 1933, AS AMENDED). PRESENTATION (AND INFORMATION CONTAINED IN IT) DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE OR THE SOLICITATION OF AN OFFER TO PURCHASE SECURITIES, IN THE UNITED STATES OF AMERICA. THE ISSUER'S SECURITIES HAVE NOT BEEN AND WILL NOT BE REGISTERED IN ACCORDANCE WITH US SECURITIES ACT OF 1933, AS AMENDED, NEITHER ARE THEY PUBLICLY OFFERED IN THE UNITED STATES OF AMERICA. IT MAY BE UNLAWFUL TO DISTRIBUTE THIS DOCUMENT IN CERTAIN JURISDICTIONS. THIS DOCUMENT IS NOT FOR DISTRIBUTION IN CANADA, JAPAN, AUSTRALIA OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD VIOLATE APPLICABLE LAW OR REQUIRE REGISTRATION. THE INFORMATION IN THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN CANADA, JAPAN OR AUSTRALIA.

Pure Biologics SA – emerging **biopharma**



Development of **first in class** biological drugs and therapeutical medical devices



Unique proprietary technologies for the development of biologically active therapeutic molecules



Value building based on generated IP



Portfolio of therapeutic projects that maximizes commercialization potential

Resources



Almost a **100** specialists, ~**35%** PhD level



1000 m² state-of-the-art labs and infrastructure



2 proprietary technological **platforms**



10 years track record of commercial and R&D projects



HQ & Laboratories
in Wroclaw Poland

CRO
R&D

2010

growth, know-how, strategy
evolution, pipeline building

2020

CRO
R&D

The Team



Leadership team



Filip Jelen, PhD, MBA
Founder & Chief Executive Officer, President

President & main shareholder of Pure Biologics, 15+ years scientific and science managing experience, both in Poland and USA as a post-doc in **Murad's (Noble prize laureate) lab in Houston, TX**. Protein engineering specialist, seasoned manager.



Romuald Harwas
Chief Financial Officer, Vice-president

Experienced financial manager and accountant, former CFO and member of the board of several companies. Managed the transition companies to the main market of the WSE, cooperated with venture capital, private equity and public-private partnership funds.



Przemyslaw Jurek, PhD, MBA
Chief R&D Officer

Scientist, inventor & manager, with background in drug development and aptamers. Oversees the pipeline and project managers, also covers business development side for new collaborations and services.



Marta Wawrzyniak, MBA
Chief Operations Officer

Skilled manager and antibody scientist, natural negotiator & efficient problem solver. Responsible for laboratory groups management, human resources and daily operations.



Richard Fox, PhD
Preclinical development director

Experienced scientist trained in **Fred Hutchinson CRC & University of Washington, Seattle, USA**, successful startup founder and former director at **Merck**. Skilled in developing, designing and executing research studies ranging from basic science through early clinical trials.



Andrzej Trznadel
Supervisory Board Chairman

Expert in the field of capital transactions, commercial law, business transformation, finance and banking and management. He managed publicly traded private equity funds, handled business transformations, issuing projects and **>20 IPOs** of technological companies.

Advisory board strengthens Pure Biologics' expertise in various aspects



Radoslaw Zagozdzon, PhD, MD
Immunooncology

Clinical immunologist trained in **Boston and in Dublin**. He's got years of medical and scientific experience, including animal research and immune system in cancer. As a consultant for Pure Biologics dr. Zagozdzon supports the team in the field of tumor models as well as in planning and analysis of **preclinical development studies**.



Julia Bar, PhD, MD
Immunooncology

Professor Bar is head of Immunopathology and Molecular Biology Division of Wroclaw Medical University. She specializes in **immunooncology, cancer biology and in regenerative medicine** and tissue engineering. She both advises the company as well as sits in the Supervisory Board.



Boguslaw Paradowski, PhD, MD
Neurology

Professor Boguslaw Paradowski is a **seasoned clinician in neurology**. For over 20 years he has been a voivodship chief consultant in the field of neurology. Today he helps Pure Biologics with the projects covering the treatment of **neurological diseases and rare diseases**, he also supports the team in topics related to **clinical trials**.



Waldemar Priebe, PhD
Cancer biology

Dr Waldemar Priebe is Professor of Medicinal Chemistry at **Division of Cancer Medicine, MD Anderson Cancer Center**. His research is around finding and developing new drugs that alter the signalling and metabolic pathways important to cancer progression and survival.



Günter Mayer, PhD
Aptamers

Professor Mayer is a **top aptamers expert** in the field and head of the research group and professor at the **University of Bonn**. He's a leader of international projects and founding director of the **Center for Aptamer Research and Development** at the University of Bonn.



Miroslava Piskorikova, PhD
Regulatory affairs

Dr. Piskorikova is widely experienced in assisting companies to understand legislation, overcome regulatory barriers and prepare registration dossiers which comply with the latest EC, EMA, FDA and EFSA requirements. Former **regulatory affairs manager in Eli Lilly (Elanco)**.

The Strategy



Two assets-discovering platforms grant **independence**

01


Drug development starts with **discovery** of lead candidates!

02

Advanced **in-house** *in vitro* approaches (no animals used)


03

State-of-the-art techniques, **proprietary technologies**



PureApta™ - granted US patent 15/760,915, EPO patent pending

The business model relies on **commercialization on generated IP**



Pure Biologics' pipeline is composed of **two research lines**



Immunooncology, oncology using bispecific antibodies (bsAb)

PB001 bsAb in CRC

PB003 Ab-ligand in NSCLC

PB004 bsAb in TNBC

Antibodies

PB006 Apt-drug in melanoma

Neurological rare diseases via medical devices (MD)

PB002 Apt-MD in NMO

PB005 Apt-MD in Myasthenia g.


Aptamers

Patented PureApta™ platform

The Science



Immuno-oncology at Pure Biologics




Source: Dranoff G. Nat Rev Cancer. 2004;4:11-22

- Early to mid- drug development, up to First-in-Human clinical trials
- **Bispecific molecules** that synergize immunological effects
- Entering **preclinical stage** in 2021
- High prevalence primary indications
- Ongoing evaluation of secondary indications

Immuno-oncology at Pure Biologics

- I/O – **most attractive** new drugs segment in recent years
- Keytruda (MSD) to become #1 drug in 2023 with **sales at > \$20 bln**
- Major big pharma is looking for in-licensing assets
- PB's goal is to **license-out assets** at preclinical / early clinical



Source: Dranoff G. Nat Rev Cancer. 2004;4:11-22

Aptamer-aided medical devices to explore rare diseases space



Immunooncology, oncology using bispecific antibodies (bsAb)

PB001 bsAb in CRC

PB003 Ab-ligand in NSCLC

PB004 bsAb in TNBC

Antibodies

PB006 Apt-drug in melanoma

Neurological rare diseases via medical devices (MD)

PB002 Apt-MD in NMO

PB005 Apt-MD in Myasthenia g.

Aptamers

Patented PureApta™ platform


Targeted apheresis – medical device approach for aptamers

MECHANISM OF ACTION

Apheresis apparatus filter contains resin with immobilized specific aptamer (use of **patented PureApta™ platform**): provides a safer, targeted apheresis procedure

MEDICAL PLATFORM

Aptamers specific towards other targets - **additional indications**




AptaPheresis as a **bolt-on** to existing apheresis machines

- Tapping into **existing infrastructure**
- Improvement to already marketed products
- **Easier market access** through big players
- Co-development in later stages




The business model – licensing-out assets




Best selling drugs are mostly **biological** molecules

Best selling drugs in 2019 (bln \$)



Deal values increase with the asset development stage




A collage of images related to biotechnology and research. It includes a woman in a white lab coat working with equipment, a close-up of a microscope, a diagram of a cell with a glowing nucleus, and various scientific illustrations of cells and molecules. The images are arranged in a dynamic, overlapping layout with a blue and green color scheme.

R&D projects in progress

PROJECT	END DATE	PROJECT BUDGET * [mln EUR]	GRANT [mln EUR]	OWN CONTRIBUTION [mln EUR]	PROGRESS 31.12.2019	PROGRESS 30.06.2020
PB001 MultiBody	DEC 2023	7.2	5.4	1.8	19.4%	24.0%
PB002 AptaPheresis	MAJ 2023	3.2	2.4	0.8	23.3%	28.1%
PB003 PureActivator	DEC 2023	9.0	6.8	9,8	8.3%	11.7%
PB004 PureBike	DEC 2023	9.1	6.7	2.4	1.1%	6.7%
PB005 AptaMG	DEC 2023	3.3	2.4	0.9	9.5%	14.5%
PB006 AptaMLN	FEB 2021	0.3	0.2	0.1	0%	19.9%
PB010 PureSelect2	OCT 2020	1.0	0.7	0.3	78.4%	87.4%
TOTAL		33.1	24.6	8.5	12.3%	17.2%

* As approved by National Centre for Research and Development

Structure of the project portfolio



Basic financial figures


P&L & Cash Flow	HY 2020	HY 2019
	000 EUR	000 EUR
Revenue from commercial services	97	243
Grant income	1 518	1 131
Operating expenses	2 655	1 783
Net profit (loss)	(1 075)	(450)

Cash flows from operating activities	(134)	(575)
Cash flows from investing activities	-	(37)
Cash flows from financing activities	(357)	2 045
Net change in cash and cash equivalents	(491)	1 432
Cash and cash equivalents	2 631	1 479

Balance Sheet	As of 30.06.2020	As of 30.12.2019
	000 EUR	000 EUR
Total Assets	4 947	4 951
Fixed Assets	1 774	1 402
Current Assets	3 173	3 549
Short-term receivables	511	238
Cash and cash equivalents	2 631	3 269
Liabilities	4 446	3 749
Long-term liabilities	1 204	855
Current liabilities	3 241	2 895
Equity	501	1 202
Share capital	37*	39

* Due to differences in the exchange rate

Market performance



DEC 2018

IPO - 0.7 mln EUR
Market Cap. - 4.9 mln EUR

MAY 2019

Sec. PO - 2.3 mln EUR
Market Cap. - 12.6 mln EUR

Autumn 2020

Public offer - ??? EUR
Market Cap. - **37.1 mln EUR**

	till 31.08.2020	2019
Price increase	220%	68%
Trading volume	786 714	563 660
Trading value *	11 100	4 300
Number of transactions	17 533	9 526
Average daily volume	4 576	2 282
Average daily trading value *	66	18

* In 000 EUR

The summary



Pure Biologics reaches for two **distinct and attractive markets**



Team of experts, building competencies, growing experience



Shared operations, optimized resources



Common strategy, synergy of technology platforms

Antibodies-based drugs



Immunooncology – most attractive new drugs segment



High demand for assets in in-licensing pharma

Aptamers-aided medical devices



Rare diseases – growing and not-saturated market



Aptamers as a new approach with limited competition



Contact

Pure Biologics S.A.

Duńska 11 street
54-427 Wrocław, Poland

info@purebiologics.com
tel. +48 570 00 28 29